search
Back to results

Validation Study of SCALA, Scale for Lateropulsion (SCALA)

Primary Purpose

Stroke

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
SCALA
Sponsored by
University Hospital, Grenoble
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Stroke focused on measuring lateropulsion, stroke, Pusher syndrome

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: All types of stroke, ≤6 months.

Exclusion Criteria: postural disorders other than stroke or body geometry disorders (e.g. limb amputation, severe deformity, bone fracture, trunk deformity with deviation of C7 greater than 30mm) interfering with balance, acute vertigo, history of severe psychiatric disease, medical instability, dementia diagnosed, and severe understanding deficits limiting assessments.

Sites / Locations

  • Grenoble University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

stroke

control

Arm Description

stroke patients, application of SCALA

Healthy individuals (patients without stroke), application of SCALA

Outcomes

Primary Outcome Measures

SCALA Reliability
Inter-rater reliability, internal consistency, measurement error of SCALA

Secondary Outcome Measures

Influence of vision on lateropulsion
Comparison of scores of items performed with and without vision
Interest of the condition without vision on the lateropulsion diagnosis from the SCALA total score.
Comparison of proportion of individuals with a lateropulsion by using the total score of SCALA based on all items (with and without vision) and that of individuals with a lateropulsion by using the total score of SCALA based only on items with vision
Evaluation of SCALA feasibility
Influence of sensory-motor, language and cognitive deficits, severity of balance and gait disorders, and stroke features (type and localization) on the time required to complete SCALA; Descriptive statistics on items judged as "not applicable"
To improve the understanding of mechanisms underpinning lateropulsion
Relation between the total score or subscores of SCALA, and stroke lesion characteristics, verticality perception, representation of longitudinal body axis in lying position, body orientation in frontal plan, weight-bearing asymmetry, and awareness of deficits.
Reliability of supplementary instrumental assessments of lateropulsion
Inter-rater reliability of longitudinal body axis representation and postural verticality perception
Criterion validity of SCALA
Comparison to Scale for Contraversive Pushing and Burke Lateropulsion Scale, which currently are considered as gold-standards to assess lateropulsion.
Descriptive analysis of data of individuals with stroke
Descriptive analysis of data
Descriptive analysis of data of healthy controls
Descriptive analysis of data including normality ranges.

Full Information

First Posted
October 7, 2016
Last Updated
September 15, 2022
Sponsor
University Hospital, Grenoble
search

1. Study Identification

Unique Protocol Identification Number
NCT03077399
Brief Title
Validation Study of SCALA, Scale for Lateropulsion
Acronym
SCALA
Official Title
Clinical Validation of SCALA, a New Rating Scale for Assessing Lateropulsion After Stroke
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2022 (Actual)
Primary Completion Date
September 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Grenoble

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Development and clinical validation of SCALA, a new rating scale for lateropulsion after stroke. A monocentric clinical study including 78 post-stroke individuals and 30 patients without stroke and/or healthy volunteers. In order to analyze the SCALA's content validity, a Delphi-type consensus process was applied prior to clinical validation. The Delphi process, including 20 international experts, has given rise to the version of the scale to be tested clinically (SCALA-V1; Paper in preparation).
Detailed Description
The protocol aims to develop and validate a new clinical rating scale assessing lateropulsion after stroke. The project is driven by the need to have a tool that better meets clinometric properties than the 2 main existing scales, the Scale for Contraversive Pushing (SCP) and the Burke Lateropulsion Scale (BLS), and by the need to have a unicist scale to assess all components of lateropulsion (i.e. body tilt, active pushing by non-paretic limbs and resistance to passive correction) regardless the mechanisms or the severity of lateropulsion and the side of the stroke lesion. The initial version (version 0) of the scale has been developed by our team in Grenoble (SCALA-V0). In a first step, an online expert consensus process (Delphi method) will give rise to a version 1 (SCALA-V1), considered as generally accepted by the scientific community. The SCALA-V1 will be validated in a monocentric clinical study. 78 individuals with stroke and 30 individuals without stroke and/or healthy controls will be included. All subjects will be comprehensively assessed during 3 weeks. During the first week will be performed many assessments used in routine in our center. These assessments will serve to describe participants and ensure that our series is comparable to others of the literature. These assessments which are not considered as outcome are: age, sex, height, weight, manual laterality, comorbidity, apraxia, executive function deficits, retropulsion, depression, and autonomy. Several other clinical assessments will also be performed during the first week, this time to serve as outcomes: stroke lesion characteristics, motor weakness, spasticity, spatial neglect, anosognosia, aphasia, hemianopsia, hypoesthesia, visual verticality, balance and gait disorders. During the second week, lateropulsion by SCALA-V1, verticality perception and spatial representation will be assessed to determine their inter-rater reliability. During the last week, mass distribution on lower limbs in frontal plan during standing position and body orientation in frontal plan during sitting position, standing position and sit-to-stand will be assessed. Editorial valorization of the clinical trial: This study will be valorized by several papers, one concerning clinometric properties of SCALA-V1 (reliability …), other(s) paper(s) about the understanding of lateropulsion, and clinometric properties of the devices assessing vertical perception and body orientation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke
Keywords
lateropulsion, stroke, Pusher syndrome

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
This study is a monocentric observational clinical study. During the first week, the assessments used in routine in our center will be performed. During the second week, the assessments of lateropulsion by SCALA-V1, postural verticality perception in sitting and the representation of longitudinal body axis in lying position will be performed twice, 2 days apart, by 2 different raters in order to determine their inter-rater reliability. During the third week, mass distribution on lower limbs in frontal plan during standing position and body orientation in frontal plan during sitting position, standing position and sit-to-stand will be assessed.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
108 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
stroke
Arm Type
Experimental
Arm Description
stroke patients, application of SCALA
Arm Title
control
Arm Type
Experimental
Arm Description
Healthy individuals (patients without stroke), application of SCALA
Intervention Type
Device
Intervention Name(s)
SCALA
Intervention Description
All items of SCALA are applied
Primary Outcome Measure Information:
Title
SCALA Reliability
Description
Inter-rater reliability, internal consistency, measurement error of SCALA
Time Frame
week 2 (assessed twice +/-2d)
Secondary Outcome Measure Information:
Title
Influence of vision on lateropulsion
Description
Comparison of scores of items performed with and without vision
Time Frame
week 2
Title
Interest of the condition without vision on the lateropulsion diagnosis from the SCALA total score.
Description
Comparison of proportion of individuals with a lateropulsion by using the total score of SCALA based on all items (with and without vision) and that of individuals with a lateropulsion by using the total score of SCALA based only on items with vision
Time Frame
week 2
Title
Evaluation of SCALA feasibility
Description
Influence of sensory-motor, language and cognitive deficits, severity of balance and gait disorders, and stroke features (type and localization) on the time required to complete SCALA; Descriptive statistics on items judged as "not applicable"
Time Frame
Week 2
Title
To improve the understanding of mechanisms underpinning lateropulsion
Description
Relation between the total score or subscores of SCALA, and stroke lesion characteristics, verticality perception, representation of longitudinal body axis in lying position, body orientation in frontal plan, weight-bearing asymmetry, and awareness of deficits.
Time Frame
weeks 1,2 and 3
Title
Reliability of supplementary instrumental assessments of lateropulsion
Description
Inter-rater reliability of longitudinal body axis representation and postural verticality perception
Time Frame
Week 2 (assessed twice +/-2d)
Title
Criterion validity of SCALA
Description
Comparison to Scale for Contraversive Pushing and Burke Lateropulsion Scale, which currently are considered as gold-standards to assess lateropulsion.
Time Frame
Weeks 1 and 2
Title
Descriptive analysis of data of individuals with stroke
Description
Descriptive analysis of data
Time Frame
Weeks 1, 2 and 3
Title
Descriptive analysis of data of healthy controls
Description
Descriptive analysis of data including normality ranges.
Time Frame
Day 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: All types of stroke, ≤6 months. Exclusion Criteria: postural disorders other than stroke or body geometry disorders (e.g. limb amputation, severe deformity, bone fracture, trunk deformity with deviation of C7 greater than 30mm) interfering with balance, acute vertigo, history of severe psychiatric disease, medical instability, dementia diagnosed, and severe understanding deficits limiting assessments.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dominic Pérennou, MD, PhD
Phone
0033 4 76767575
Email
DPerennou@chu-grenoble.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Aurélien Hugues, PT, PhD
Phone
0033 4 76767575
Email
ahugues@chu-grenoble.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dominic Pérennou, MD, PhD
Organizational Affiliation
University Hospital, Grenoble
Official's Role
Principal Investigator
Facility Information:
Facility Name
Grenoble University Hospital
City
Grenoble
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dominic Pérennou, MD, PhD
Email
dperennou@chu-grenoble.fr
First Name & Middle Initial & Last Name & Degree
Aurélien Hugues, PT, PhD
Email
ahugues@chu-grenoble.fr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Validation Study of SCALA, Scale for Lateropulsion

We'll reach out to this number within 24 hrs